Belgian 'crown' ready to knock US migraines on the head

April 1, 2014 by James Panichi, Catherine Boitard
A model wears the classic model of Cefaly Technology's new head band device to be used against migraines at Cefaly Technology in Herstal, Belgium, on April 1, 2014

A small technology company based in southern Belgium is set to take on the giant US market with its crowning achievement: an anti-migraine headband.

The product of years of medical and technological research, the device is a diadem fitted with electrodes designed to take the edge off migraines before they develop into acute blinding pain.

Migraine, a deep headache which develops behind the eyes and can last for days, is estimated to stalk to some degree the lives of about one in seven adults around the world, World Health Organization data shows.

It appears to be less common in the Far East, but overall affects up to three times more women than men owing to differences in hormonal activity.

The band, developed by the Belgian company Cefaly Technology, is worn across the forehead, and sends electric currents to facial nerves.

Although the device is not a cure for severe headaches, the manufacturers believe it could stop the transition from "episodic" migraines to the more severe "chronic" category.

The WHO says that migraine is one of the top 20 causes of disability in terms of years of healthy life lost.

The battery-powered headband, which was given the green-light by the US Food and Drug Administration (FDA) in March, will be the first device with this design available in the United States.

According to Cefaly Technology's managing director Pierre Rigaux, while the headband is already on the European market, the long-awaited FDA approval will open the way to a 25-percent boost in sales over the next five years.

The device will hit the US market at a time when medical experts are putting more trust in non-pharmaceutical responses to migraines.

Giles Elrington, the medical director of the National Migraine Centre, a British charity research centre, said that techniques targeting the patient's head, in contrast to the use of drugs affecting the whole body, will be a "huge area of development in coming years."

FDA approval is key

Such stories are common in Europe's medical technology industry which is being driven by small businesses.

According to data compiled by MedTech Europe, an alliance of Europe's medical technology industry associations, the sector employed more than 575,000 people in 2012, and comprised almost 25,000 medical technology companies in the EU.

"European companies like this one are at the forefront of innovation," said MedTech Europe's chief executive Serge Bernasconi.

The United States accounts for 41 percent of the European medical technology export market, with China a distant second at 10 percent and Japan third, at seven percent.

A view of the US model of Cefaly Technology's new head band device to be used against migraines, at the Cefaly Technology headquarters in Herstal, Belgium, on April 1, 2014

The figures show the importance to small companies of obtaining FDA approval for those products which require it.

One of the creators of the migraine headband told the AFP that international technological developments in the field mean that "the course had been set" for the use of electrical stimulation to treat a number of pathologies, including headaches and insomnia.

Before the FDA approval, Cefaly Technology's short-term prospects in Europe had been reasonable, with 80,000 anti-migraine devices sold before 2009, but its turnover was only 3.0 million euros ($4.13 million) for 2013.

That has now changed: the small company, based outside the town of Liege and with just 10 employees, expects to sell 10,000 units a month in the US market.

Non-invasive treatment

Germany is by far Europe's leading exporter of , however statistics suggest smaller countries Netherlands, Belgium, Ireland and Switzerland, are punching above their weight.

The reason for that, according to Bernasconi, is more administrative than cultural: medical multinationals often have their headquarters or production centres in these countries, and med-tech start-ups tend to orbit around them.

Europe's highly decentralised regulatory system may also play a role, with the myriad national regulatory bodies creating a more nimble and responsive landscape than the large federal system in place in the United States.

As a result, new technologies can be introduced in Europe years ahead of distribution in the United States, although a shortage of capital to support research can push European countries to head across the Atlantic, cap in hand.

Founded in 2004 by a 58-year-old medical doctor and an engineer, Cefaly Technology took its first steps by researching the area of sports medicine, a field in which electrical stimulation of muscles was nothing new.

The challenge for the company was to apply those techniques to the external stimulation of nerves, where electrodes had traditionally been implanted to be effective—for example, into the spinal cord to treat chronic pain.

Rigaux believes that that research was a turning point, because US authorities "immediately saw a new treatment, which was non-invasive and not involving drugs, as a positive."

Explore further: FDA approves electric headband to prevent migraine

Related Stories

FDA approves electric headband to prevent migraine

March 11, 2014
The U.S. Food and Drug Administration said Tuesday it approved a Belgium-made nerve-stimulating headband as the first medical device to prevent migraine headaches.

FDA approves new magnet device to treat migraines

December 15, 2013
(HealthDay)—The U.S. Food and Drug Administration has approved the first device aimed at easing the pain of migraines preceded by aura—sensory disturbances that occur just before an attack.

Don't let migraines ruin your holidays

December 26, 2013
(HealthDay)—The holidays can challenge the estimated 30 million migraine sufferers in the United States as they try to deal with crowds, travel delays, stress and other potential headache triggers.

Acute migraines more apt to turn chronic with poor treatment

June 28, 2013
(HealthDay)—People who receive inadequate treatment for acute migraine headaches are more likely to develop chronic migraines, according to a new study.

Botox injections associated with only modest benefit for chronic migraine and daily headaches

April 24, 2012
Although botulinum toxin A ("Botox") injections are U.S. Food and Drug Administration approved for preventive treatment for chronic migraines, a review and analysis of previous studies finds a small to modest benefit for ...

Does more stress equal more headaches?

February 19, 2014
A new study provides evidence for what many people who experience headache have long suspected—having more stress in your life leads to more headaches. The study released today will be presented at the American Academy ...

Recommended for you

Phase 3 trial confirms superiority of tocilizumab to steroids for giant cell arteritis

July 26, 2017
A phase 3 clinical trial has confirmed that regular treatment with tocilizumab, an inhibitor of interleukin-6, successfully reduced both symptoms of and the need for high-dose steroid treatment for giant cell arteritis, the ...

A large-scale 'germ trap' solution for hospitals

July 26, 2017
When an infectious airborne illness strikes, some hospitals use negative pressure rooms to isolate and treat patients. These rooms use ventilation controls to keep germ-filled air contained rather than letting it circulate ...

Researchers report new system to study chronic hepatitis B

July 25, 2017
Scientists from Princeton University's Department of Molecular Biology have successfully tested a cell-culture system that will allow researchers to perform laboratory-based studies of long-term hepatitis B virus (HBV) infections. ...

Male hepatitis B patients suffer worse liver ailments, regardless of lifestyle

July 25, 2017
Why men with hepatitis B remain more than twice as likely to develop severe liver disease than women remains a mystery, even after a study led by a recent Drexel University graduate took lifestyle choices and environments ...

Mind-body therapies immediately reduce unmanageable pain in hospital patients

July 25, 2017
Mindfulness training and hypnotic suggestion significantly reduced acute pain experienced by hospital patients, according to a new study published in the Journal of General Internal Medicine.

Research examines lung cell turnover as risk factor and target for treatment of influenza pneumonia

July 24, 2017
Influenza is a recurring global health threat that, according to the World Health Organization, is responsible for as many as 500,000 deaths every year, most due to influenza pneumonia, or viral pneumonia. Infection with ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.